Amarin Investors Still Treading Water (AMRN)

Amarin Investors Still Treading Water

At this point, Amarin (Nasdaq: AMRN ) investors are used to hearing about delays from the Food and Drug Administration concerning Vascepa's NCE status -- but today they were faced with a delay of a different kind.

Amarin originally stated that it would make the decision whether to get a Vascepa sales team together toward the end of November, but the company recently announced that it's not yet ready to commit. The decision will now be deferred to the first half of December, but Amarin is still eyeing a drug launch in the early part of 2013.

Health care analysts Max Macaluso and David Williamson discuss this news and possible scenarios for Amarin in the following video.

The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air without NCE status for Vascepa, the drug's success is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Report this Comment On December 01, 2012, at 5:39 PM, kthor wrote:

looks like AMRN management just want to sell the company ...
Report this Comment On December 01, 2012, at 6:55 PM, RHMASS wrote:

I just don't know why people can't read between the lines. Clearly the negotiations are well on the way either with one of a few serious suitors. However it is not at the stage for announcement as the NCE designation from FDA has a meaningful relevance concerning the final offering price. The fact that the co kept on delaying hiring for its own sales force makes its current status obviously clear. However the co can't go ahead and announce the deal as the final price hasn't been set. As an investor of AMRN, I see the announcement as another hint to the direction of the co. I would have been concerned if the co announces a definitive plan to hire sales people.
Report this Comment On December 01, 2012, at 7:05 PM, skm1965 wrote:

RHMA SS analysis makes a lot of sense.
If you were to hire sales people today--and announce a buyout deal 2-3 weeks from now--how would newly hired people feel.
The new employees will say--Amarin did not tell us the truth and there could be lawsuits.
Once a decision is made-one way or other-then hiring sales people makes sense--as Reliant was sold in Nov.2007 after 3 yrs.of launch.Most sales people worked for Reliant for at least 3 yrs.and some probably were kept beyond 2007.
Report this Comment On December 01, 2012, at 7:11 PM, skm1965 wrote:

FYI -Abingworth who has a person on the board and they own more than 5% of shares want to sell.
Joe Z.,CEO has to consider a sales seriously.
We all know that if Reduce-It study produces good results,Anchor patents are confirmed-FDA approval is likely by Aug.2013--the Amarin Stock could be worth over 60-80$/share in 2016.
Look at Warner Lambert stock from 1996 to 1999 as WL and Pfizer launched Lipitor.
Pfizer could have bought WL for 20 bil.$ in 1996--but they paid 90 bil.$ in 1999 to acquire WL.

updated Moments ago Sponsored by:
	DOW	15,207.19	-99.98	-0.65%
	S&P 500	1,639.80	-15.55	-0.94%
	NASD	3,433.61	-29.69	-0.86%

AMRN	$6.77		-0.12	-1.75%
Amarin Corp plc (A…		CAPS Rating:

GSK	$52.54		-0.40	-0.76%
GlaxoSmithKline		CAPS Rating:

ABT	$37.57		-0.15	-0.40%
Abbott Laboratorie…		CAPS Rating:

My Watchlist

0

Amarin Investors Still Treading Water

Comments from our Foolish Readers

Report this Comment On December 01, 2012, at 5:39 PM, kthor wrote:

Report this Comment On December 01, 2012, at 6:55 PM, RHMASS wrote:

Report this Comment On December 01, 2012, at 7:05 PM, skm1965 wrote:

Report this Comment On December 01, 2012, at 7:11 PM, skm1965 wrote:

Add your comment.

Compare Brokers

Report This Comment

Sending report...

Today's Market

Create My Watchlist

You don't seem to be following any stocks yet!

Related Tickers